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Abstract
The rise of high-technological innovations in the mid- to late- 20th and early 21st centuries 
has required the establishment of equally innovative agencies and institutions to guide 
these technological innovations. This thesis examines the emergence and evolution of 
Genome Canada, which was created to oversee the proliferation and direction of genomic 
research within Canada.  This thesis examines how genomic research developed in 
Canada throughout the late 1980s to early 2000s, why it became necessary to create 
Genome Canada, how the networked model chosen was seen as the preferred model, and 
how Genome Canada has evolved to date.
This case study of Genome Canada is important because it reveals how public institutions 
that guide innovation emerge and how they evolve over time. As well, it is important 
because it reveals how the model used in the genome policy sector may be used again in 
the future as a framework for establishing other similar institutions.
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Chapter 1: Introduction
1.1 Purpose, Objectives and Research Questions
As technology becomes more pervasive within our lives and enters areas that 
engender public concern, governance systems have a responsibility to become involved 
in regulating the processes and products of technologically based research projects.  This 
is especially true when the research conducted has not only substantial potential for 
bettering human life but also potentially dangerous or unpredictable side effects.  One 
such case is genomic research.  Decoding the very blueprints of life has struck both the 
imagination and the fears of people in our society.  Genomic research has been 
undertaken for well over a half century now, and the results are beginning to unlock 
exciting new areas of possible technological development that engender both hopes and 
fears, some examples of projects currently underway include understanding cancer 
genomics, Autism genomics to even potato genomics.1  This has led governments, as well 
as academic institutions and private sector agencies to determine key features of the 
governance and funding system of such programs. In Canada, this has led to the creation 
of a genome research network consisting of a national agency and several regional 
centres. While the national agency is primarily responsible for fostering, facilitating and 
funding genome research in Canada, the core mandate of the regional centres is to 
develop and maintain the research infrastructure and to manage the research.2   For 
purposes of this thesis, Genome Canada and the regional centres are collectively referred 
to as the ‘Genome Canada Research Network’ (GCRN).
1 Genome Canada, “Health Projects”: http://www.genomecanada.ca/en/portfolio/project/health.aspx
2 Genome Canada, “Vision-Mission-Mandate”:  http://www.genomecanada.ca/en/about/vision.aspx and 
Genome Canada, “Regional Centres”: http://www.genomecanada.ca/en/centres/
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Genomics is the science of understanding how genes interact with each other and 
their environments to make living things do what they do.3  By manipulating genetic 
sequences scientists can change a biological being in some significant ways.  Examples 
of such genomics research covers a spectrum of different research portfolios from 
understanding how immunity to infectious diseases works, how to grow hardier and more 
productive crops, how to make forests resistant to disease and even how to develop new, 
cleaner sources of energy.4  The importance of this research is its ability to impact 
humanity at a very fundamental level whether it be through the foods that we eat, the 
methods through which we produce energy or our own ability to fight off diseases. 
The central purpose of this thesis is to provide an overview and analysis of the 
effects that federalism have had on the configuration, governance, operation, and research 
agendas of the Genome Canada network. Toward that end, several interrelated research 
questions are addressed. 
1. How and why was Genome Canada created? 
2. How is Genome Canada governed?  
3. How is the regionalized genomic research network structured?
4. When, how and why were the regional centres created?
5. How are the regional centres governed?
6. What is the research focus of each regional centre?
7. How is the genomic research network funded?
The first two questions are addressed in Chapter 2 (The Genesis and Governance of 
Genome Canada), the subsequent four research questions are addressed in Chapter 3 
(Structure, Governance & Research Foci of Regional Genomic Network), and the last 
question is addressed in Chapter 4 (Resourcing the Canadian Genomic Research 
Network). 
3 Genome Canada, “What is Genomics”, http://www.genomecanada.ca/en/info/DNA/genomics.aspx. 
4 Ibid.
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1.2 Theoretical Perspectives: (The Influences of Canadian Federalism on Canadian 
Genome Research)
While interesting and important in their own right, the answers to these questions 
provide some valuable insights on the effects of Canadian federalism on Canadian 
genomic research. In particular, they provide insights on the effects that federalism has 
had on the emergence and evolution of the structure, research agenda, and funding of the 
GCRN. 
Co-operative and Competitive Federalism
This thesis is informed both by the two theoretical perspectives and two models of 
factors that shape policy and program initiatives within Canadian federalism.  The two 
perspectives are the socio-centric and state-centric perspectives, and the two models are 
collaborative and competitive federalism. Whereas the socio-centric perspective 
postulates that policy and program initiatives are the products of societal factors, the 
state-centric perspective postulates that such initiatives are the products of state or 
governmental factors.5 Invariably, both of these perspectives profile state and societal 
institutions and interests in explaining policy and program initiatives.  These perspectives 
point to two alternative sets of factors to focus on in explaining determinants of policy 
and program initiatives. It is important to note that they are not mutually exclusive, and 
focusing on a combination of factors highlighted by each of these two perspectives 
provides a fuller and more accurate description of the factors that influence policy and 
program initiatives.  Within the context of this case study, attention is devoted to the 
5 Alan C. Cairns, “The Governments and Societies of Canadian Federalism”, Canadian Journal of Political 
Science, Vol. 10, No.4 (Dec., 1977), pp. 695-725.
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effect that factors highlighted by these two theoretical perspectives had on the genesis, 
configuration, operation, and funding of the GCRN. 
In explaining policy and program initiatives, analysts also tend to employ, either 
explicitly or implicitly, the collaborative and competitive models of federalism. Whereas 
the former explains policy and program initiatives as the products of collaboration 
between the senior orders of government, the latter explains them as products of 
competition between them.6 While these two ideal type models provide us with valuable 
insights, in practice many policy and program initiatives are products of a combination of 
collaboration and competition among two or more of those governments. It is with that in 
mind, that this thesis devotes attention to patterns of collaborative and competitive 
federalism in relation to key aspects of the emergence, evolution, operation and funding 
of the GCRN.
Networked Federalism
Another useful framework for analyzing the GCRN within the context of the 
Canadian federal system is ‘networked federalism’. This framework is based on the 
notion that all organizations are made up of nodes, and that nodes are responsible for the 
generation of information and decision making within organizations regardless of their 
precise configurations.  Janice Gross Stein postulates that such nodes exist within the 
following four general categories of organization: 
6 On Cooperative Federalism: Anthony Harold Birch, Federalism, Finance, and Social Legislation in 
Canada, Australia, and the United States (Oxford: Clarendon Press, 1955), pg. 33.
Fred Cutler and Matthew Menddolen, Canada in Explaining Federalism: State, Society and Congruence in 
Austria, Belgium, Canada, Germany and Switzerland edited by Jan Erk (London; New York: Routledge, 
2008), pg. 47.
On Competitive Federalism: Ronald L. Watts, The MacDonald Commission Report and Canadian  
Federalism, Publius, Vol. 16, No. 3, The State of American Federalism, 1985 (Summer, 1986), pg. 195.
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• Tribes: These are generally kin-based organizations that are relatively closed and 
self-sufficient and are usually very difficult for others to access or engage.
• Markets: These are multi-organizational entities in which more than one 
organization or agent is involved in decision-making and the transactional 
activities related to it.  Each organizational entity has its own decision making 
nodes and operates within the context of markets that are relatively open and 
accessible for a wide range of organizations to operate either on their own or in 
collaboration with others. 
• Hierarchies: These are vertically linked or integrated bureaucratic organizational 
frameworks. In a highly hierarchically structured organization, generally 
information travels from the bottom to the top and decisions travel in the other 
direction.  Hierarchies are susceptible to what Gross Stein refers to as 
‘bottlenecks’ caused by failures to ensure that information and decisions flow 
without disruptions. 
• Networks: These are organizational frameworks consisting of a multiplicity of 
organizational entities and a multiplicity of organizational nodes that, unlike 
hierarchies, are not structured in a highly regimented and inflexible hierarchical 
manner.  
Ideally networks permit nodes to communicate with each other regardless of their relative 
position in the organization.  A failure in one node is mitigated by the information or 
decision being horizontally routed through other branches of the network.  Flexibility and 
redundancy allow for rapid adaptation to sudden changes in the network.7 Gross Stein 
7Janice Gross Stein, Networked Federalism from Canada: The State of the Federation 2006/07 Transitions: 
Fiscal and Political Federalism in an Era of Change, pg. 347.
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applies these principles to federalism by explaining that government bureaucracies have 
traditionally behaved as hierarchies but are progressively moving and should strive to 
behave more like networks.  She adds that today it is imperative to foster and facilitate 
the opening of policy space to non-governmental organizations and to encourage 
cooperation between governmental bureaucracies. Something that Gross Stein only seems 
to infer, rather than explicitly say, is that it seems reasonable to presume hierarchies and 
networks may coexist within a single organization.  As this thesis reveals, this certainly 
seems to be the case with Genome Canada. 
Triple Helix Model
In analyzing some aspects of the organization and operation of the GCRN, this 
thesis also relies on the Triple Helix model, specifically Triple Helix II. The Triple Helix 
is an important analytical tool when considering research and development initiatives 
involving the government, academia and industry.  The use of the Triple Helix helps 
analysts identify key actors who perform key roles in establishing and operating research 
and development systems.  The Triple Helix model is detailed more fully at the beginning 
of Chapter Two. Here it suffices to note that the Triple Helix model is an analytical 
concept produced to capture the relationships between key sets of players commonly 
involved in knowledge generation and dissemination systems.  Unlike the double helix of 
the genetic code (on which the concept is based) which has two genetic strands, the triple 
helix has three key organizational strands.8
The three organizational strands of importance within the triple helix that are 
likely to be very significant within the knowledge generation and dissemination systems 
8 This paragraph is a paraphrase of the Triple Helix model from Peter W. B. Phillips, Governing 
Transformative Technological Innovation: Who’s in Charge? (Cheltenham, UK; Northampton, Mass.: 
Edward Elgar, 2007), pg. 41.
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are the government helix, the industry helix and the academic helix.  As the names 
suggest the government helix is made up of governmental agencies and agents, the 
academia helix is made up of universities and research agencies and agents that co-exist 
within the public and private sectors, and the industry helix is made up of private sector 
commercial or industrial agencies and agents  that are generally presumed to be involved 
for some venture capital, fiscal benefit or as a necessary partner in the commercialization 
of technology from the research the policy is focused.  The key to the creation, operation 
and sustainability of the triple helixes is finding a working balance between each of these 
three components. If a working balance does not exist then problems can develop. 
Examples of such problems are noted in subsequent chapters.
7
1.3 Contribution of the Thesis
This thesis makes a contribution to the existing literature both at the theoretical 
and empirical levels. At the theoretical level it sheds some additional light on the effects 
that federalism has on the organization of agencies that exist and operate within the 
context of multi-level governance wherein an array of governmental and non-
governmental actors undertake major research initiatives.  At the empirical level it 
provides a detailed analysis of interesting and important governance, management and 
funding issues related to the GCRN. The contributions of this thesis at the theoretical and 
empirical levels is likely to be of some practical value in conceptualizing, constructing, 
and analyzing pan-Canadian research networks and other types of networks in the future. 
8
Chapter 2: Genesis and Governance of Genome Canada
2.1 Introduction
Genome Canada is a public not-for-profit corporation established in 2000 to 
coordinate genomic research in Canada.  The organization adopted a federated 
governance model with the central national body of Genome Canada existing in a 
network with its regional affiliates. These include Genome Atlantic, Genome Quebec, the 
Ontario Genomic Institution, Genome Prairie, Genome Alberta, and Genome B.C., all of 
which are also non-profit corporations themselves.  This chapter provides an explanation 
of the genesis and the governance of Genome Canada. 
2.2 The Genesis of Genome Canada
In explaining the genesis of Genome Canada it is useful to apply the ‘Triple 
Helix’ model that was utilized by Peter Phillips in a comprehensive analysis on governing 
innovation. The model, which was developed by sociologists Etzkowitz and Leydesdor, is 
very useful in examining the roles and relationships of different actors responsible for 
scientific and industrial innovation 9  As noted in Chapter One, the Triple Helix model 
emphasizes the existence of three main actors in innovation promotion and governance: 
government, academic and industry.  
There are three versions of the Triple Helix model.  Triple Helix I views 
government, university and industry as three different institutions that use agencies to 
negotiate between each other.  Triple Helix II, the version used in this thesis, view the 
three as communication devices that link groups into networks to coordinate activities 
9 Peter W. B. Phillips, Governing Transformative Technological Innovation: Who’s in Charge? 
(Cheltenham, UK; Northampton, Mass.: Edward Elgar, 2007) pg. 41.
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efficiently.  Triple Helix III views the institutions as able to overlap to certain degrees, for 
example permitting universities to assume certain levels of governing authority or certain 
industries to perform strictly scientific research rather than technological 
commercialization.10  
The value of the Triple Helix model is that it helps to shed light on the 
interconnectivity, cooperation between and the need for balance amongst the three 
helixes.  This chapter uses the Triple Helix to shed light on the effect that each of the 
three helixes performed in the creation of Genome Canada.
The events that led to the creation of Genome Canada started in the 1980s when 
existing and emerging centers of excellence began to perform research in various 
genomic fields such as cancer in British Columbia, agriculture in the Prairies, human 
health in Ontario, fisheries in the Atlantic region, etc. This research initiated at the same 
time that at the international level a joint United States and British genomic project 
entitled the Human Genome Project (HGP) was established for the purpose of mapping 
the entire human genome.  From 1987 to 1992 genome researchers within Canada were 
coalescing with the intentions of lobbying the federal government for additional support 
and funding to engage in the HGP.11 Using the HGP as a catalyst to foster interest in 
genomic research, the genomic researchers in Canada began to organize to lobby to get 
Canada involved in the HGP.  They accomplished their objective in 1992 when Canada 
was accepted as a member of the HGP. 
10 Loet Leydesdorff and Henry Etzkowitz, The Triple Helix as a Model for Innovative Studies 
(Conference Report, Science & Public Policy, Vol. 25(3) (1998)), pg. 195-203.
11 Bartha Maria Knoppers and Charles Scriver, Genomics, Health and Society: Emerging Issues for Public 
Policy (Government of Canada, 2003) Available at: 
http://www.policyresearch.gc.ca/doclib/IR_OTHER_genomicbook_e.pdf, pg. 5.
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Both prior to and after Canada became involved with the HGP, the regional 
research groups began to develop into a network to lobby the federal and provincial 
governments for funding needed to improve the research infrastructure and to fund 
various types of genomic research projects.12  This period offered a unique shift in the 
relations between the organizations in that they began to cooperate in a more 
comprehensive and sophisticated manner. This shift contributed substantially to the 
establishment of an emerging network that would eventually become more organized and 
mature during the Genome Canada period. Efforts to institutionalize and increase 
research were based on recognition that despite some talented genomic researchers in 
Canada, such as Dr. Michael Smith, who won the Nobel Prize in Chemistry in 1993 by 
providing the world with one of the key tools for genomics research, Canada’s 
performance in the field, and particularly in the area of the HGP, was disappointing.13 Part 
of the reason that they were underperforming is that the researchers were not only 
underfunded by the national government, but they were also encumbered by the slow 
pace of decision-making and inflexibility on the part of federal bureaucrats who 
dominated the governmental helix. The underfunding and inflexibility of those 
bureaucrats led the research nodes to turn to the industry helix for funding.  
Eventually, the Canadian federal government learned from this process that its 
traditional bureaucratic institutions could not be relied upon to adequately deal with the 
needs of something as fast paced and responsive as genomic research, thus requiring the 
government to reconsider standard practices and to facilitate the creation of a public non-
12 “The Human Genome Project and Its Ethical, Legal and Social Implications” Prepared by: Tim Williams, 
Science and Technology Division 26 July 2000, Available at: http://dsp-psd.tpsgc.gc.ca/Collection-
R/LoPBdP/BP/prb0008-e.htm (last checked October 16, 2009)
13 Genome Atlantic “History”: http://www.genomeatlantic.ca/faq.php 
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profit corporation (i.e., Genome Canada), to organize and assist the various research 
agencies that formed during this period.
After the regional genomic research groups achieved their objectives of getting 
Canada involved in the HGP and increasing government funding for genomic research 
infrastructure and research output, they focused on making Canada an increasingly larger 
player in the international genomic research agenda.14  The research groups had mixed 
results with this particular objective. While they made some progress on developing the 
genomic research infrastructure and conducting some research, they also encountered a 
major hurdle as a fiscal crisis rocked the Canadian federal government that led to budget 
cuts in many areas, including genomic research.15  As funding levels continued to drop 
during the mid- to late-90s, the continually evolving group of genomic researchers began 
to become frustrated by the decreasing level of support from the federal government and 
started to look for other sources of funding.  Some of them, such as the B.C. network, 
relied more on the provincial government, and others relied more on funding from 
industry. The reliance on industry concerned some because it contained potential risks in 
having their research agenda shaped by the interests or preferences of the funding 
industries. 
This greater reliance on alternative funding culminated in a crisis for the HGP 
when in 1998 Celera Genomics, a private corporation from the United States, came 
forward proclaiming it was entering the race to map the human genome and planned on 
patenting the decoded genome. Celera Genomics had pegged 2000 as the completion 
date, three years before the HGP’s anticipated completion.16 The news created some 
14 Ibid.
15 Jean Soucy and Marion G. Wrobel, Federal Spending: Changing Trends (Government of Canada, 2000), 
Available at: http://dsp-psd.tpsgc.gc.ca/Collection-R/LoPBdP/CIR/872-e.htm
16 James Shreeve, The Genome War (New York: Ballantine Books, 2004), pg. 117.
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consternation among policy elites when Celera stated that it would patent the human 
genome and not make their genetic information publicly available without cost.17 
However, Celera’s ambitions were stymied when the United States President, Bill 
Clinton, announced that the American government would not permit patenting of human 
genetic research.18  Celera’s stocks, along with several other stocks and assets within the 
biotechnology sector, plummeted precipitously following the announcement.  Canada 
reacted as well, but not as swiftly as the United States, because such expeditious reaction 
was less necessary as Canada had already rejected the patenting of genetic discoveries for 
higher life forms,19 and created a committee to investigate the controversy over patenting 
genetic discoveries. The committee’s work lasted from 2000 to 2003 and concluded that 
reform was needed to the Patent Act to take into account the innately personal nature of 
human genetic research.20  This sudden challenge caused several countries within the 
HGP to reevaluate their situations, and in Canada this led to a resurgence of interest from 
the federal government in the area of genomic research. Thus, from 1998 until 2000 
federal funding was once again increased to encourage a shift of genomic research away 
from a dependency on industry funding. The increase was made possible because by the 
mid-90’s the federal government’s financial situation had improved.21  
17 Ibid.
18 Alan Axelrod and Charles Phillips, What Every American Should Know About American History 
(Holbrook, Massachusetts: Adams Media Corporation, 2007), pg. 354.
19 “The Human Genome Project and its Ethical, Legal and Social Implications” makes reference to 
President and Fellows of Harvard College v. Canada (Commissioner of Patents) (T.D.), 21 April 1998, 
where the Supreme Court ruled against Harvard College’s attempts to patent their “Harvard Mouse” in 
Canada.
20 “Genetics, Testing & Gene Patenting: Charting New Territory in Healthcare” (January 2002) available at: 
http://www.health.gov.on.ca/english/public/pub/ministry_reports/geneticsrep02/report_e.pdf (last accessed 
October 16, 2009)
21 “Federal Spending: Changing Trends” Prepared by: Jean Soucy, Economics Division and Marion G. 
Wrobel, Senior Analyst Revised 27 March 2000, available at: http://dsp-psd.tpsgc.gc.ca/Collection-
R/LoPBdP/CIR/872-e.htm#D. Federal Budgets of 1990, 1991 and 1992 and(txt) 
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The creation of a government funded network of non-profit public corporations, 
rather than a privately funded for-profit corporation, in 2000 resulted from two 
interrelated factors. First,  private sector genomic research firms were not very interested 
in research in this area because they had to deal with intransigent and inflexible federal 
and provincial regulatory bureaucracies that could not respond very quickly or well to the 
innovative nature of genomic research which required much faster response mechanisms 
to industry changes and scientific-technological breakthroughs. Another reason that 
private enterprises did not get involved in genomic research was that they could not 
patent their research in ways that they wanted.  A case in point as mentioned previously 
was Celera Genomics, a privately owned and funded genetic research enterprise in the 
United States that developed a new method of mapping genes.  One crucial distinction to 
note here is that Celera was permitted to patent its process for mapping genes; they 
simply were not permitted to patent the genes they were mapping because that plan had 
met with widespread disapproval amongst the American people.22    In Canada, members 
of the public were also opposed to private corporations owning the rights to the 
fundamental structure of their genetic makeup.  The reasoning being that as a matter of 
public interest it is important for government to insure that any research and development 
occurring within genomics is properly regulated and appropriate.
In February 2000 Canada took the final step in supporting the academic helix with 
its research agenda by awarding Genome Canada a total of 300 million dollars for its 
setup and initial operations.23  Given the increasingly complex nature of the genomic 
research groups that had been developing during the pre-Genome Canada period, 
22 Shreeve, pg. 13 and Axelrod and Phillips, pg. 354.
23Genome Canada, “Media”: http://www.genomecanada.ca/en/medias/news.aspx?i=2 
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eventually it became a necessity to have a national, not-for-profit enterprise that would 
spearhead and oversee genomic research funding and regulation in Canada.  The federal 
government had been a constant source of frustrations for this sophisticated network 
because its bureaucratic ponderous nature had made it insufficiently adaptable to act in 
light of new and changing situations such as the one posed by competitors like Celera 
Genomics.  Although it was slow in responding and adapting to changing circumstances, 
the federal government had made a significant positive financial contribution to the 
creation of Genome Canada and its regional centers (Genome Atlantic, Genome Quebec, 
Ontario Genomic Institute, Genome Prairie, and Genome B.C.; later Genome Alberta).
By 2003 the HGP had essentially mapped the entire human genome, but further 
research would be necessary to fill in areas that remained only vaguely understood. 
Genomic research in Canada had grown exponentially during this time and Genome 
Canada had already succeeded in several competitions that were quickly defining the role 
Canada was to play in the genomics agenda. Since 2003 Genome Canada has become a 
leading international player in the areas of GE3LS (Genomics and its Ethical, Economic, 
Environmental, Legal and Social Aspects) research and has successfully participated in 
several international competitions.24  It has done this within its federated structure, which 
has provided a good balance between cooperation and competition and centralization and 
decentralization.
Although the foregoing overview of the genesis of Genome Canada focused 
primarily on the interaction among the three key sets of actors identified by the Triple 
Helix, it reveals the dynamics of cooperative and competitive federalism involving the 
federal and provincial governments in relation to private sector agencies. More 
24Genome Canada, “About Genome Canada”: http://www.genomecanada.ca/en/about/
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specifically, it reveals the new way that the federal government became and remained 
involved in this particular policy sector vis-à-vis the provincial governments and the 
private sector. While specific discussions regarding Genome Canada’s mandate and 
position within the federal bureaucracy will be forthcoming, for this summary the federal 
government facilitated and supported the establishment of a relatively autonomous 
national research agency (i.e., Genome Canada) operating at arm’s length from it, which 
was mandated to ensure constructive coordination and possibly cooperation among 
various agencies from the three components of the Triple Helix, while at the same time 
operating at arm’s length from each of those agencies.  
16
2.3 Governance Framework of Genome Canada
Genome Canada’s governance framework consists of a Board of Directors 
comprised of 16 individuals drawn from academic, private and public sector 
communities.25  The Board has seven committees established to assist in its operations, 
those being an Executive Committee, Audit Committee, Investment Committee, Election 
Committee, Corporate Governance Committee, Compensation Committee and a Science 
and Industry Advisory Committee.  The Board members come from various backgrounds 
and draw from genomic institutions both within Canada and the United States; the 
present Canadian Board members are drawn from institutes within the provinces of 
Ontario, Quebec and Alberta.  Five of the members are ex-officio advisors, these being 
the Presidents of the Canadian Institutes of Health Research, the Natural Sciences and 
Engineering Research Council of Canada, the Social Sciences and Humanities Research 
Council of Canada, the National Research Council and the Canada Foundation for 
Innovation.
The following sections explain the function and composition of each of the 
Committees of Genome Canada’s  Board of Directors in order to provide  a full 
understanding of the governing bodies of Genome Canada, but also those of the regional 
centres because the regional centres have committees that mirror Genome Canada.
The Executive Committee exists to oversee the direction and management of the 
property, business and affairs of Genome Canada.  Its membership consists of at 
minimum three and at maximum six members of the Board of Directors, appointed by the 
Board of Directors upon receipt of advice from the Election Committee.  A majority of 
25Genome Canada, “ Governance: Board of Directors”: 
http://www.genomecanada.ca/en/about/governance/directors.aspx 
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members must be independent directors, independent entailing that the member is free of 
any business or other relationship which could materially interfere with the exercise of 
their independent judgment subject to appropriate disclosure.  Genome Canada’s 
President and Chief Administrative Officer are ex-officio, non-voting members of the 
Executive Committee.  The Committee’s mandate includes acting on behalf of the Board 
of Directors when the Board is not in session and to exercise all or any powers vested in 
the Board except those to adopt, amend or repeal by-laws of the Corporation or appoint 
any directors of the Corporation and any other acts which must be performed by the 
directors themselves under the law.  The Committee is also limited from passing 
resolutions that would cause the Corporation to commit funds without a prior specific 
mandate from the Board of Directors.26
The Election Committee is responsible for overseeing the process for selection of 
new directors to the Board and members to Committees as well as reviewing, from time 
to time, Board and Committee size, composition and profile.  Its membership consists of 
at minimum three members of the Board, appointed by the Board upon receipt of advice 
from the Election Committee with the majority being independent directors.  The 
President and CEO is an ex-officio voting member while the Chief Administrative 
Officer is an ex-officio non-voting member.  The Election Committee’s primary 
responsibility is in overseeing a formal and transparent selection process for any 
vacancies or transitions within the Board of Directors and Committees.  What is required 
in that process is described in detail in the Committee’s brief.27
26Genome Canada, “Governance: Committees”: 
http://www.genomecanada.ca/en/about/governance/committee/executive.aspx 
27Genome Canada, “Governance: Committees: Election Committee”: 
http://www.genomecanada.ca/en/about/governance/committee/election.aspx 
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The Audit Committee assists the Board of Directors in fulfilling its legal fiduciary 
obligations with respect to matters involving the integrity of accounting, auditing, 
financial reporting, internal controls and financially related legal compliance functions of 
Genome Canada.  Its membership consists of a minimum of four members of the Board 
of Directors; similarly to the Executive Committee, members are appointed by the Board 
of Directors upon receipt of advice from the Election Committee and must be considered 
independent directors.  All or some of the Audit Committee must be financially literate 
and at least one must have accounting or related financial management expertise.  The 
President and CEO, Vice President Finance and Chief Administrative Officer are ex-
officio, non-voting members of the Audit Committee.  The Audit Committee is 
responsible for Genome Canada’s accounting, risk management, auditing, financial 
reporting and all other matters of a financial responsibility all of which contain numerous 
sub-headings explaining each element in detail.28   
The Investment Committee is responsible in assisting the Board of Directors in 
fulfilling its legal and fiduciary obligations with respect to matters involving the 
investment management of any funds at the disposal of Genome Canada.  Its membership 
consists of at minimum three members of the Board of Directors, appointed by the Board 
under receipt of advice from the Election Committee, with a majority of independent 
directors.  All or some of the members are to be financially literate and at least one must 
have accounting or related financial management expertise.  One notable difference is 
that the President and CEO is an ex-officio voting member while the Vice President 
Finance and Chief Administrative Officer are ex-officio non-voting members.29
28Genome Canada, “Governance: Committees: Audit Committee”: 
http://www.genomecanada.ca/en/about/governance/committee/audit.aspx 
29Genome Canada, “Governance: Committees: Investment Committee”: 
http://www.genomecanada.ca/en/about/governance/committee/investment.aspx 
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The Corporate Governance Committee oversees responsibilities with respect to 
developing, reviewing and assessing governance principles and guidelines for Genome 
Canada that are consistent with high standards of corporate governance.  Its membership 
consists of at minimum three members of the Board of Directors appointed by the Board 
upon receipt of advice from the Election Committee consisting of a majority of 
independent directors.  The President and CEO is an ex-officio voting member and the 
Chief Administrative Officer and Genome Canada’s legal counsel are ex-officio non-
voting members.  The Corporate Governance Committee’s responsibilities include 
reviewing the frequency of meetings of the Board and Committees, developing 
evaluation processes for the Board and Committees, insuring with management 
appropriate orientation and education programs for existing and new directors, 
monitoring fiduciary and legal responsibilities externally and benchmarking best 
practices internally, and acquiring expert advice for Genome Canada when necessary. 
The full list of the Committee’s responsibilities is included in the Committee’s brief.30
The Compensation Committee is responsible for compensation for Genome 
Canada’s employees.  Its membership consists of at minimum three members of the 
Board of Directors appointed by the Board on receipt of advice from the Election 
Committee consisting of a majority of independent directors.  The Compensation 
Committee deals with compensation at all levels as well as determining performance 
evaluations for any awarding of bonuses.31
Initially adopted in 2008, the Science and Industry Advisory Committee was 
created in response to Genome Canada’s growing research position internationally.  Its 
30Genome Canada, “Governance: Committees: Corporate Governance Committee”: 
http://www.genomecanada.ca/en/about/governance/committee/corporate.aspx 
31Genome Canada, “Governance: Committees: Compensation Committee”: 
http://www.genomecanada.ca/en/about/governance/committee/compensation.aspx 
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responsibilities are to assist the Board in fulfilling its objectives of excellence and 
leadership in genomics research and the ethical, environmental, economic, legal and 
social aspects (GE3LS) relating to this research in Canada and provide to the Board of 
Directors strategic advice on approaches and directions that contribute to the 
corporation’s achievement of its objectives.  Its membership consists of at minimum nine 
to a maximum of sixteen members of the Board of Directors appointed by the Board 
upon receipt of advice from the Election Committee.  The composition must include 
individuals from Canada who are internationally recognized in science and industry and 
in fields relevant to the ethical, environmental, legal and social aspects of genomics 
research.  The Committee is tasked with advising the Board of Directors regarding 
emerging scientific research opportunities and challenges, international trends and 
possible collaborations, areas of strategic socio-economic importance to Canada, and 
overseeing the quality, outcomes and impact of research programs and activities 
performed by Genome Canada.32
32Genome Canada, “Governance: Committees: Science Committee”: 
http://www.genomecanada.ca/en/about/governance/committee/science.aspx 
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2.4 Conclusions
To reiterate, the dual purpose of this chapter has been to provide an overview of 
the genesis and the governance of Genome Canada. This chapter has revealed that 
Genome Canada was the product of lobbying efforts undertaken by a network of 
researchers based in academia that originally collaborated to lobby the federal 
government to partake in the international HGP project, to increase government funding 
for genomics research, and to create a relatively independent non-profit corporation that 
would provide national leadership and funding for genomics research.   The creation of 
Genome Canada can also be traced to the special efforts of a company within the industry 
sector (i.e., Celera Genomics) to appropriate this important and sensitive genomics 
research agenda. The perceived threat posed by Celera Genomics strengthened the 
working relationship between the governmental and academic helixes to develop and 
resource the Canadian genomics research network and to expedite the funding and 
completion of research.
The second part of this chapter examined the governance framework of Genome 
Canada, including the composition and mandate of the Board and its various committees. 
The composition and mandates of these committees and the Board are important to note 
not only for understanding them, but also because many of the regional centers operate 
examined in the next chapter developed similar governance frameworks.   
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 Chapter 3: Structure, Governance & Research Foci of Genomic Research Network
3.1 Introduction
Whereas the objective in the previous chapter was to explain why and when 
Genome Canada was created and how it is governed, the objective of this chapter is to 
explain how the genome research network is structured, how each regional centre is 
governed, and the research focus of each centre within the network. The explanations 
provide valuable insights into the effect that federalism has had on the structure of the 
genomic research network, as well as the governance and research focus of each regional 
research centre. 
3.2 How is the Regional Genomic Research Network Structured?
The regional genomic research network was formed during the initial round of 
funding by Genome Canada known as Competition I. During the deliberation process for 
Competition I there was discussion over how many regional centres should be 
established. During Competition I it was decided by those overseeing the Competition 
that the genomic research network should consist of five regional centers: Atlantic, 
Quebec, Ontario, Prairie, and BC. Initially there were five regional research centers but 
eventually a sixth would be added when the Alberta researchers and the provincial 
government decided to establish Genome Alberta and have it operate separately and 
independently from Genome Prairie. 
In 2005 Genome Alberta broke away from Genome Prairie in what was seen as a 
peaceful separation by mutual consent, thus becoming a separate regional genomics 
centre within the context of the Genome Canada research network. As there is no 
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documentation on what precisely led to the separation of Genome Alberta from Genome 
Prairie there are at least three possible explanations.  The first is simple practicality; 
Genome Alberta and Genome Prairie had both reached sufficient capacity in their 
capability to perform genomic research that Genome Alberta could exist as its own 
regional centre without jeopardizing the abilities of Genome Prairie to conduct its own 
regional research.  The second potential explanation stems from the research interests of 
the groups in Alberta relative to those of Saskatchewan and Manitoba.  Alberta’s 
economic and research interests focus more on the energy and human health sectors, 
while Saskatchewan and Manitoba have a greater interest in bio-products and agriculture. 
The separation would allow for a greater focusing of each centre’s specific agenda and 
acknowledges and respects the unique interests of each centre equally.  The third possible 
explanation is that the Alberta provincial government preferred a greater Alberta focus 
regarding research initiatives, and encouraged the creation of Genome Alberta in an effort 
to increase the accountability and transparency of its share of provincial funding.
Alberta’s secession from Genome Prairie resulted in a change from a structure 
consisting of three research centers, each of which involved only a single province (i.e., 
Quebec and Ontario and B.C.) and two that involved multiple provinces each (i.e., 
Genome Atlantic and Genome Prairie), to a structure consisting of four centers each of 
which involved only a single province (i.e., Quebec, Ontario and B.C. and Alberta), one 
that involved four provinces (i.e., Genome Atlantic), and one that involved two provinces 
(i.e. Genome Prairie). 
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3.3 What is the Research Focus of Each Regional Research Centre?
One of the major decisions that had to be made in establishing the genomic research 
network was the precise research focus or functions of each regional research centre. 
Following some extensive negotiations on the matter, it was decided that each regional 
centre would conduct an array of genomic research, rather than each of them specializing 
on one particular area of research.  
The creation of multiple regional centres with research agendas with multiple broad 
research foci, rather than a single research focus, was intended to advance several 
objectives including: providing diversity in the research agenda; increasing specialization 
in several research areas; increasing expertise in various research areas; and minimizing 
groupthink across the network.  Furthermore, establishing provincial and regional 
genome centers responsible for conducting an array of research projects related to various 
categories of genome research, rather than have each of them specializing in one 
particular area of research, made it possible for provincial governments to invest in 
research projects that interested them in centers located within their province or region. 
This seems quite evident in the funding provided by the BC government to Genome BC, 
and by the Alberta government to Genome Alberta.  If the single-specialization model 
had been used, public funds from some provincial governments for research that 
interested them would have had to be directed to research centers in other provinces.  If 
the provincial governments were unwilling to do that, research funds would have been 
reduced substantially.  For example, if an Atlantic province wished to do a forestry 
research project in their province, but in a single-specialization system forestry research 
was performed by Genome B.C., then those provincial funds would be travelling across 
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Canada, and the costs of the project would likely be substantially greater as well.  In the 
multiple foci system that was chosen, forestry projects could be undertaken either by one 
or more academic groups operating within separate research centres across the country on 
their own or by several groups working collaboratively across the network.  This 
operational framework also helps to reduce the potential for groupthink developing in a 
subject specific research climate as academics and scientists specializing in different 
fields exist in the same regional centre, providing ample opportunity for cross-
specialization discussion.
3.4 How are the Regional Centres of the Research Network Governed? 
In Chapter Two the governance structure used by Genome Canada was described 
as consisting of a Board of Directors supported by various committees.  The governance 
frameworks for regional centres are quite similar to that of Genome Canada. Like the 
national agency, they have a governance board and a set of governance and operations 
committees. Moreover, the governance and management framework is very similar, 
though not identical, across the regional centres. There are two different models of 
governance frameworks across the regional centers.  Genome BC, Genome Alberta and 
Genome Quebec have a governance framework that is very similar to Genome Canada 
with a Board of Directors and a number of Executive Committees.  The other three 
centres have a slightly different governance model. Genome Prairie, the Ontario 
Genomics Institute, and Genome Atlantic each have a Board of Directors, but while the 
Board offers insight and direction, the President and CEO and other high ranking 
executives (CFO, Vice Presidents, etc.) do not serve on the Board, because they are 
designated as staff members. There are also differences in the configuration of 
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governance and operational committees across the regional centres.  For example, 
whereas some have an ethics committee (e.g., Genome B.C and Genome Alberta), others 
do not (e.g., Genome Quebec). Similarly whereas some have an executive committee 
(e.g., Genome BC and Genome Quebec), others do not (e.g., Genome Atlantic). 
Table 3.1: Executive Framework for various Genomic Centres 33
Genomic Centre Executive Committees
Genome Canada Executive, Audit, Investment, Election, 
Corporate Governance, Compensation, 
Science and Industry Advisory.
Genome BC Executive, Audit, Investment, Governance 
& Nominations, Society & Ethics, Business 
Development, Compensation, and Science.
Genome Alberta Audit, Investment, Governance, Elections, 
Ethics.
Genome Prairie No Committees; high ranking executives 
(CFO, Vice Presidents, etc.) serve as staff.
Ontario Genomic Institute No Committees; high ranking executives 
(CFO, Vice Presidents, etc.) serve as staff.
Genome Quebec Executive, Audit, Investment, Governance 
(Genome Quebec’s Governance Committee 
also oversees elections), Strategic and 
Scientific Advisory Board (SSAB).
Genome Atlantic No Committees; high ranking executives 
(CFO, Vice Presidents, etc.) serve as staff.
3.5 Conclusions
When examining the structure and governance of Genome Canada and its regional 
centers, what becomes apparent is the existence of a highly complex and interconnected 
network that has a surprising depth of flexibility and self-governance at the regional 
level.  Decision making processes at the regional level are highly decentralized with 
Genome Canada recognizing the effectiveness of its regional centers in performing their 
33 Information for this section is drawn from each Genomic Centre's websites and documents.  It is possible 
that those centres marked as having No Committees have informal internal organizational groupings that 
perform the same function as the Committees of other centres, but those centres described as having 
Committees clearly identify their Committees as such and contain adequate public information on their 
composition, creation and mandate.
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functions and pursuing their objectives without heavy amounts of top-down oversight. 
Further, the regionalized structured that has been institutionalized allows for diversity in 
the precise membership and governance frameworks. 
What is also apparent is the interest in creating a balanced network that does not 
privilege some regional centers over others, either in terms of their precise research 
agenda or in the amount of financial resources that are assigned to them.  They are all 
free to determine the precise focus of their research agenda and all can submit research 
proposals in the funding competitions. This regionalized network structure facilitates both 
competition and cooperation amongst its nodes and reduces risks of groupthink, 
bottlenecks or similar administrative problems noted within the context of networked 
federalism theory in Chapter One.
For groupthink, the primary concern here is when a group of researchers working 
in a single facility or location focus on areas of expertise and do not have an open 
environment that includes researchers from other fields interacting with them on a daily 
basis the risk of the group adopting a rigid and inflexible view becomes greater. The 
research environment generated through the creation of a networked, federal system 
permits researchers to be in contact with researchers in their own fields in their own 
research facility and while still having access to researchers in other centres within their 
own fields of expertise as well as other fields of expertise who can offer alternative views 
and insights into research methods and problems that may not have occurred had that 
proximity not existed.
Another problem that multi-loci networked systems help to deal with are 
bottlenecks. Bottlenecks tend to be prevalent and problematical in overly hierarchical 
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centralized systems in single facilities or locations.  Network system has the unique 
ability of adapting to potential bottlenecks by redirecting any decision making that is 
being held up by a failing node through another network arm that is responsive to the 
transfer.  Furthermore, by widening the entirety of the decision-making process more 
comprehensive decisions can be made in shorter times with more input from different 
research facilities in different locations.  While this process does carry some risk of 
redundancy and an overload of voices being applied to a decision making process, such 
issues can be mitigated by agreed upon objectives and procedures that members of 
networks adhere to as constructive members of the network.
Administrative problems exist when it comes to the accountability of funds going 
through a networked system.  It makes sense that provincial governments are keenly 
aware of where their research funding is going, and that many would prefer that their 
research funds remain in their province for the sake of political patronage.  Were a single 
centre of excellence system adopted, then funds from one province would be spent 
entirely in another province, something that could cause stress between the researchers 
and the province.  A networked system with various research interests in each province 
solves this issue, permitting provincial governments to fund research on a spectrum of 
topics conducted by research centres located within their own provinces.
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Chapter 4: Resourcing the Genomic Research Network
4.1 Introduction
This chapter provides an overview of the financial resourcing of the genomic 
research network in Canada. It consists of two major sections. Section one provides an 
overview of the financial resourcing of Genome Canada and section two provides an 
overview of the financial resourcing of the regional research centers.  The second section 
examines the funding received from three major sources:  governmental sources, non-
governmental sources, and Genome Canada. 
4.2 Resourcing of Genome Canada
Since its inception Genome Canada has invested $1.815 billion. Of this 
approximately 50% ($915 million) was provided by the Government of Canada, and 
$900 million was provided in the form of co-funding from provincial governments and 
non-governmental sources. Genome Canada’s governmental funding constitutes 69% of 
its overall funding, or approximately $1.252 million broken down into the following 
percentages: Federal funding through Genome Canada 44%, provincial funding 19%, 
other federal funding 6%.  Genome Canada’s non-governmental funding constitutes 31% 
of its overall funding, or approximately $562.65 million, broken down into the following 
percentages: international funding 19%, industry funding 8%, institutional funding 4%. 
These percentages of funding since Genome Canada’s inception in 2000 are profiled in 
the pie chart below. 
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Table 4.1: Genome Canada Funding
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4.3 Resourcing of Regional Genomic Centers
The funding made available to each of the regional centers comes from four sources: 
Genome Canada; provincial sources, be they the provincial governments directly or 
institutes, departments or funding bodies funded by provincial governments; and non-
governmental sources, typically industry or research groups with strong interest in the 
research of the centres; and some international sources whether they be governmental or 
otherwise.  This section will go through each of the regional centers individually and 
discuss what information each has made publicly available regarding their level of 
funding and funding sources.  The information reveals that there is no uniformity 
amongst the regional centers regarding the form or degree of disclosure of funding 
sources.  Thus, while some of the larger centers like Genome BC, Ontario Genomic 
Institute and Genome Quebec have annual reports with detailed financial statements that 
make it far easier to establish the level of funding and the precise sources of their 
34 http://www.genomecanada.ca/en/about/ 
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funding, it is much more difficult to ascertain funding levels and sources for other 
centers. This is particularly true for Genome Prairie and Genome Alberta.   In the case of 
Genome Atlantic, their list of projects was sufficiently manageable that an analysis of the 
budget for each project made it possible to clearly identify funding sources. 
4.3.1 Funding of Genome Atlantic
Genome Atlantic credits Genome Canada for contributing half of its overall funding 
and its provincial governmental partners and the federally funded Atlantic Canada 
Opportunities Agency (ACOA) and other agencies for providing supplementary 
funding.35  Genome Atlantic’s list of projects each indicates what funders supported each 
project. The list includes the following governmental and non-governmental agencies: 
Genome Canada, ACOA, the provinces of Nova Scotia and New Brunswick (Nova Scotia 
is mentioned in four of their eight projects), Fisheries and Oceans Canada, Scotian 
Halibut Ltd., Oryzon Genomics, Dalhousie University, Memorial University of 
Newfoundland, Nova Scotia Agricultural College, University of Saskatchewan, Genome 
Prairie, Agriculture and Agri-Food Canada, Genome Spain, and several Spanish 
universities and governmental departments.  Their most in-depth project, the Atlantic 
Medical Genetics and Genomics Initiative (AMGGI), contains a list of fifteen funders.36
4.3.2 Funding of Genome Quebec
Funding for Gnome Quebec is provided primarily by the Québec Ministère du 
Développement économique, de l’Innovation et de l’Exportation (MDEIE), Genome 
Canada, and other partners.  More specific information regarding specific contributors 
and specific amounts are found in the annual reports. The financial statements in Genome 
35Genome Atlantic, “About Genome Atlantic”: http://www.genomeatlantic.ca/aboutus 
36Genome Atlantic, “Projects”: http://www.genomeatlantic.ca/projects/view/2-
Atlantic_Medical_Genetics_and_Genomics_Initiative_AMGGI 
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Quebec`s 2009-2010 Annual Report indicate that in that fiscal year the contributions were 
as follows: Genome Canada $138 million, Government of Quebec $122 million, Canada 
Economic Development $431,000, VRQ $3.76 million, Cancer Care Ontario $3.1 
million, Genome Prairie $1.947 million, FQRNT $500,000, FRSQ $439,000, MSSS 
$100,000, Natural Resources $100,000, and Other $71,851.37
4.3.3 Funding of Genome Ontario
The financial statements contained in Ontario Genomic Institute’s 2010 Annual 
Report list Genome Canada and the Government of Ontario’s Ministry of Research and 
Innovation as key funding sources; sources other than these two are recognized as 
unrestricted or restricted contributions and are recorded separately.38  In 2010 it received 
$25 million from Genome Canada; the Government of Ontario Ministry of Research and 
Innovation contributed an additional $5 million while external contributions, denoted as 
“Other” in the financial statements, amounted to a mere $100,000.39  The financial 
statements in the 2009 Annual report revealed that Genome Canada contributed 
approximately $31 million, but there were no contributions from either the Government 
of Ontario or others.  It is important to note funding in particular years was low due to the 
nature of competitions and that this funding is project based not operational based.  It is 
interesting to note that those financial statements revealed that to advance the 
commercialization of its research, the Ontario Genomics Institute purchased common 
shares in Genomics Ontario Inc., a for-profit entity which provides investment for certain 
37Genome Quebec, Annual Report 2009-2010, available at: 
http://www.genomequebec.com/v2009/gq/publications/publications/rapportAnnuel/GQ-AnnualReport-
2009-2010-FINAL.pdf, pg. 23.
38Ontario Genomic Institute, 2010 Annual Report Financial Statements, available at: 
http://www.ontariogenomics.ca/sites/default/files/OGI%20Annual%20Report%202010%20and
%20Financials.pdf , pg. 6.
39 Ibid., pg. 10.
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commercialization activities, as well as provided that organization with a loan to fund its 
operations.40  With specific mention to projects, that same year OGI reported $67 million 
in project funding and had a list of projects funded that fiscal year.41  Funding given for 
operations, separate from project funding, is stated as $1 million from Genome Canada.42
4.3.4 Funding of Genome Prairie 
Genome Prairie indicates it has received $188 million in research activity since its 
inception in 2000. The funding has been provided by Genome Canada along with various 
other agencies from the governmental, business and university sectors.43  An annual 
report lists only the amounts Genome Canada has provided for various research activities, 
but does not list the information regarding the precise level of funding provided by other 
entities.  In recent years Genome Prairie received $101.5 million, of which $47.51 
million was provided by Genome Canada.44  Genome Prairie’s 2009-2010 Annual Report 
mentions Western Economic Diversification Canada as a leading partner in Genome 
Prairie’s involvement in four Western Canadian Genomics Networks: Western Canadian 
Vaccine Network (WCVNET), Canadian Flex Genomics Initiative (CFGI), Canadian 
Brassica Genomics Network (CBGN) and the Societal Impacts of Genomics Network 
(SIGNet).  Of particular note, the Western Canadian Vaccine Network receives funding 
from the Bill & Melinda Gates Foundation.  
The 2009-2010 Genome Prairie Annual Report lists 109 institutions (i.e., universities, 
governments and industries).45  However, 'partner' does not necessarily mean they have 
40 Ibid.
41 OGI, 2010 Annual Report, pg. 6 and 10.
42 OGI, 2010 Financial Statements, pg. 10.
43 Genome Prairie, “FAQ”: http://www.genomeprairie.ca/NewsMedia/FAQ.aspx 
44 Genome Prairie, “Projects”: http://www.genomeprairie.ca/portals/0/Projects%20List%20Updated
%20January%202010.pdf  
45 Genome Prairie, 2009-2010 Annual Report, available at: http://www.genomeprairie.ca/LinkClick.aspx?
fileticket=uOmERQd6ptA%3d&tabid=40 , pg. 10.
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provided any funding for the regional center. In many cases the partners are actually 
involved in joint research projects where Genome Prairie funding is utilized. Canadian 
governmental funding agencies included the Governments of Canada, Alberta, Manitoba, 
Saskatchewan and Quebec.   Canadian University contributors include Alberta, British 
Columbia, Calgary, Dalhousie, Laval, Lethbridge, Manitoba, McGill, Ottawa, Prince 
Edward Island, Regina, Ryerson, Saskatchewan, Simon Fraser, Toronto, Waterloo and 
Western Ontario.  Non-Canadian University contributors include the College of 
Agriculture (Nagpur, India), Delft University of Technology (Netherlands), National 
University of Singapore, Oregon State, Swedish University of Agricultural Sciences, and 
the Universities of Adelaide (Australia), Auckland (Australia), California (Davis), 
Edinburgh, Giessen (Germany), and Versailles Saint-Quentin-en-Yvelines (France). 
International partners include the European Union along with institutes in India, Ireland 
and the United States.  
4.3.5 Funding of Genome Alberta
Funding partners for Genome Alberta include several governmental agencies within 
Canada as well as some international agencies.  According to information on Genome 
Alberta's website, Canadian governmental funding agencies include: the province of 
Alberta, Genome Canada, Genome Quebec, Agriculture and Agri-Food Canada,  Western 
Economic Diversification Canada,  Industry Canada, Alberta Agricultural Research 
Institute, Alberta Heritage Foundation for Medical Research, Alberta Ingenuity 
Foundation, Alberta Network for Proteomics Innovation, Alberta Science and Research 
Authority, BioTools Incorporated, Canadian Foundation for Innovation, Capital Health 
University Hospital Foundation, MDS Sciex, Sun Microsystems of Canada Inc., the 
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University of Alberta, the University of Calgary and the University of Lethbridge. 
International funding sources include BMBF, a federal department of Germany, and 
GABI-WPG, a German Plant Biotechnology Industry Consortium.46  
4.3.6 Funding of Genome B.C.
Genome BC’s institutional evolution is unique amongst the other regional centers. 
The reason for this is that it had already been highly institutionalized and it was granted 
substantial funding by the provincial government even before the creation of Genome 
Canada. The BC provincial government has awarded Genome BC $307 million dollars in 
funding since its inception in 2000. By doing so, it out-funded the other provincial 
governments, including those of larger provinces such as Ontario or Quebec.  Recently it 
awarded an additional $50 million to Genome BC for the period from 2008 to 2015.47 The 
provincial contributions to other regional centers have been substantially less since their 
inception.  For example, Genome Prairie was awarded only $120 million over the same 
timeframe despite the fact that initially it had three provincial governments, and 
subsequently two, from which to access funds.48  
This funding provided by the BC provincial government to Genome BC gives the 
latter a much more flexible and autonomous position within the greater network of 
Genome Canada. The level of funding set the regional center up as a powerful and 
important node within the network.  This has allowed Genome BC to go so far as to host 
competitions on its own accord without the need for a Genome Canada wide 
Competition.49  This also allowed Genome BC to expand the network of genomic 
46 Genome Alberta, “Funding Partners”: http://www.genomealberta.ca/about/partners/ 
47 Genome BC, 2008 Annual Report, available at 
http://www.genomebc.ca/aboutus/publications_resources/documents/GenomeBC2008AnnualReport.pdf 
48 Genome Prairie, Annual Reports, available at http://www.genomeprairie.ca/about_genome_prairie.html 
49 Genome BC, “Portfolio: Timeline”: http://www.genomebc.ca/portfolio/timeline/ 
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research to research agencies that focused on areas of interest to Genome BC that did not 
readily fit into areas of research of interest or importance to Genome Canada.  By 
providing funding to these other research agencies, Genome BC was helping to broaden 
and enhance the positive achievements of the network as a whole. A major reason for the 
consistently high level of provincial funding for Genome BC is that its primary research 
focus, namely cancer, has a higher level of public support than some other areas of 
genomics research.  
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4.4 Resourcing of the Network through Funding Competitions
A substantial portion of the funding for the regional genomic research centers has 
been provided through a series of funding competitions by Genome Canada.  The five 
funding competitions were or are: Competition I, Competition II, Competition III, ABC 
Competition/Theme I, and Post ABC Competition/Theme II. The key features and 
importance of each of these are discussed in turn below. In doing so, some attention is 
devoted to the purpose, funding strategies and effects of various competitions. The key 
features of each of the funding competitions are profiled in Table 4.1.
Table 4.2: Key Features of Funding Competitions
Projects 
Submitted
Time Unique Elements
Competition I 275 received, 
17 selected
7 months - Created five Genome Centers.
- Open Letter of Intent method led 
to more applications than 
anticipated.
Competition II 64 received,
34 selected
7.5 months - First “true project” competition.
- Registration Packages replace 
Letter of Intent method.
- Packages vetted by regional 
centers, seeing far less rejected 
projects.
Competition III Unclear 13 months - Registration Package requires 
further details, doubling 
application size since Comp. I.
- First Competition where funding 
was not already available.
- Due Diligence Review added to 
application procedure.
- GE3LS, intellectual property, 
information sharing and 
international collaboration also 
become increasingly important 
issues.
ABC Competition/ 
Theme I
58 Letters 
received,
12 months - Return to revamped Letter of 
Intent method.
38
11 Themes 
considered,
2 selected
- GE3LS issues require 2 pages of 
the application package, which are 
now 11 pages in length.
4.4.1 Competition I
Initially Genome Canada needed to develop a formal network to manage its 
various science and technology platforms that it intended to fund.  This objective was 
addressed within the requirements of Competition I by having interested research teams 
put forward Letters of Intent for research projects that were coupled with the objective of 
creating five genomic centers across Canada.50  One interesting point to consider is how 
geography, or more precisely provincial and regional economies, could have influenced 
the creation of the regional research centers but did not. Originally there were five themes 
Genome Canada considered important to Canada: agriculture, health, forestry, fisheries 
and the environment.51  During Competition I it was decided to create five centers: 
Genome BC, Genome Prairie, the Ontario Genomic Institute, Genome Quebec and 
Genome Atlantic.  Given the geographic locations of the centers, research themes could 
have been assigned along the following lines: Genome Atlantic for fisheries, Genome BC 
for forestry, Genome Prairie for agriculture, etc.  However, Genome Canada did not 
select this model.  Instead, each of the genome centers could undertake research within 
any one or more of the five general themes.
To reiterate, dispersing the expertise for research themes across the network, 
rather than consolidating them in each center, allowed for greater collaboration within 
and across centers, and allowed for greater flexibility and innovation within each center. 
For example, researchers working on an environmental project could use not only the 
50 Eric Warren and Peter Phillips, Working Paper on Guidelines and Evaluation Criteria for Funding 
Competitions: A Comparison of Structure,  pg. 5
51 Ibid., pg. 3
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expertise of other researchers at their center to complement their own expertise, but also 
that of members of other regional centers in Canada, or even those in other countries. 
Consolidating expertise for each theme only in one of the centers could have created less 
collaboration across centers.  Moreover, it could also have stymied some cross 
fertilization across the thematic areas, or the problem of groupthink, as experts in one 
centre may have failed to devote attention to some facets of research that fell outside their 
own specialty and that of their colleagues at their respective centres.
According to the interim report of Genome Canada, this formative stage focused 
on three objectives: establishing a solid network between Genome Canada and its 
regional centers to encourage project merging and cooperation to see more efficient use 
of infrastructure and funding; offer professional management to allow researchers to 
focus on research; and obtain necessary infrastructure to accommodate a shift to large 
scale research projects.52
During the selection process of the research projects, Genome Canada played a 
role investigating where projects could be pooled together to more efficiently use 
available infrastructure and funding.  For example, it considered whether a fisheries 
proposal from Genome Atlantic could be bundled with a similar fisheries project from 
Genome BC provided both centers agreed.  This encouraged greater cooperation and 
made the combined projects more appealing for funding given the larger scale of the new 
combined project, as large-scale was a predominant requirement of Competition I’s 
guidelines.53  While at this early stage cooperation and collaboration were merely 
recommended to similar projects, eventually Genome Canada became increasingly 
52 Genome Canada, “Interim Report”, available at: http://www.genomecanada.ca/medias/PDF/EN/Five-
year_Evaluation.pdf, pg. 13.
53 Warren and Phillips, pg. 3
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committed to fostering such cooperation to the point where the practice eventually 
became commonplace and a central focus of Genome Canada’s subsequent funding 
Competitions.
The introduction of professional management services also greatly benefited 
genomic research in Canada.  Prior to Genome Canada a primary source of funding for 
genomic research was tri-council funding (i.e. SSHRC, NSERC, CIHR), which involved 
individual research groups applying for grants in which they also had to provide their 
own management services such as accounting, increasing the amount of administrative 
downtime researchers had to allocate away from performing actual research.54  Following 
the establishment of Genome Canada’s research network, the regional centres oversaw 
the professional management of selected projects, becoming the primary agents for 
project monitoring and program administration.55  Although this was mostly beneficial it 
required additional due diligence procedures in funding Competitions to insure projects 
were financially viable.56
The interim report strongly applauded Genome Canada for establishing the 
necessary infrastructure.57  Establishing a national public corporation to oversee genomic 
research led to the consolidation of various research infrastructures and a comprehensive 
record of what infrastructure was available and necessary to achieve Genome Canada’s 
objectives.  The funding granted by the federal government for Genome Canada also 
allowed for the expansion of infrastructure to regional centers, such as Genome Atlantic, 
that otherwise would not have been able to acquire sufficient funding to purchase such 
54 Interim Report, pg. 3
55 Ibid.
56 Ibid.
57 Ibid., pg. 13
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equipment otherwise.58  This added infrastructure also helped promote the efficiency and 
overall success in Canada’s research endeavors.
Genome Canada’s first competition was described as somewhat ill defined, being 
too open, and lacking clarity in its agenda.  Consequently, it produced too many project 
proposals, many of which could not survive the application process.  Another reason that 
so many proposals were received is that at that point an application, even for the creation 
of a research centre, only required a Letter of Intent along with a five page explanation of 
what was planned and required.  Genome Canada received 275 Letters of Intent for 
projects, much more than it had anticipated.  Of those, 73 passed the first stage of 
Genome Canada review.  Of those 73, only 31 were invited to submit full proposals. 
Eventually 17 of those 31 full proposals were finally approved for funding.  Thus, of the 
275 original Letters of Intent less than one-tenth made it to the final stage.  According to 
Warren and Phillips the requirements for recommendations were too broad and open 
requesting little more from applicants than that their proposals be large-scale, genome-
wide, and in a sector considered important to Canada (those being agriculture, health, 
forestry, fisheries, or the environment).59  There were no explicit references to project 
content at all.
Spending time and effort on projects that in some cases had nothing to do with the 
areas which Genome Canada was interested in funding was a terribly inefficient method 
of proceeding.  If fewer projects had been submitted they could have been reviewed in a 
shorter time frame and with less cost. Interestingly, however, the process of going from 
the original 275 Letters of Intent to the 17 funded projects and the five genome centers 
58 Interim Report., pg. 29
59 Warren and Phillips, pg. 3
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took only seven months, which was a shorter period than for any of the future 
Competitions.60  The proposals only being five pages likely contributed to this short 
timeframe.  Warren and Phillips describe the timeline for Competition I as follows:
• September 15, 2000 – Call for Letters of Intent and circulation of guidelines
• November 17, 2000 – Letters of Intent due to Genome Centers, 275 received.
• November 30, 2000 – Initial round of screening by Genome Centers’ Board of Directors, 
73 Letters of Intent chosen for submission to Genome Canada.
• December 2000 – Of the 73 proposals, 31 chosen by Genome Canada’s Board of 
Directors to develop into full proposals.
• January 26, 2001 – Full project proposals due.
• March 2, 2001 – Completion of international peer review, 17 projects and 5 Genome 
Centers chosen.
• March-April, 2001 – Board of Directors of Genome Canada deliberates based on 
recommendations from international panel.
• April 4, 2001 – Announcement of Competition winners.
Total time: 7 months61
Several important developments occurred during the Competition I period 
following Genome Canada’s creation.  First, Competition I created the five regional 
genome centers in an efficient and accountable manner.  Second, Competition I also made 
it clear to Genome Canada that more detail and clarity would be needed in future 
Competitions to prevent the same problem of over-applications that occurred in 
Competition I.  Thirdly, despite the unexpected quantity of submissions, Competition I 
still remained the least time consuming of the Competitions.  The review process was 
completed in seven months.  The efficiency was made possible largely because many of 
the submissions obviously did not align with Genome Canada’s interest or the general 
criteria that had been articulated.  This made it possible for the 275 proposal to be 
reviewed and ranked by the regional centers in only thirteen days in the fall of 2000. 
60 Warren and Phillips, pg. 10.
61 Ibid.
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4.4.2 Competition II
Four months following the completion of Competition I, Genome Canada 
announced the beginning of Competition II.  The shortness of time between the 
completion of Competition I and the commencement of Competition II was because 
whereas Competition I was intended primarily to establish the five genome centers and 
formalizing the genomic research network in Canada, Competition II was the first “pure 
project” Competition. The number of research projects that would eventually be selected 
through Competition II was twice that of Competition I.62  The other reason for the short 
timeframe between the first two Competitions is that there was little reason to hesitate 
since Genome Canada already had the funding available from the initial grants provided 
by the federal government.  Warren and Phillips describe the process for Competition II 
as follows:
• July 19, 2001 – Request for registration package
• November 1, 2001 – Registration packages due to Genome Canada
• December 13, 2001 – 64 full proposals sent to Genome Canada for international review 
• February, 2002 – International peer review panel evaluates project proposals
• March, 2002 – International peer review meeting
• April, 2002 – Genome Canada board of directors, on advice of the international review, 
announce 34 successful proposals.
Total Time: 7.5 months63
The key steps in the Competition II process were somewhat different than those 
for the Competition I process.  Competition I began with the submissions of Letters of 
Intent.  Genome Canada had experienced issues with that process, and thus experimented 
in Competition II with a more formalized and directed registration package to make 
Letters of Intent more easily evaluated along Genome Canada’s criteria.  This increased 
62 Warren and Phillips, pg. 1
63 Ibid., pg. 11
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the materials necessary from five pages to seven, and reinforced the practice of regional 
genome centers playing a significant role.64  Warren and Phillips explain that the reason 
for this is that proposals had to be vetted by the regional centers before being forwarded 
to Genome Canada for review.  The completed registration packages given to Genome 
Canada were principally used to develop international review panels chosen from the full 
proposals that the regional centers decided would be reviewed by those panels.65  The 
regional centers were also heavily involved in the formulation of registration packages, 
partly as a means of making the performance review process easier downstream.66  This 
also indicates a certain degree of regional authority in Competition II that seemed less 
apparent in Competition I, for each regional center could send proposals to Genome 
Canada at their own discretion.67
This regional assurance that proposals met Genome Canada’s eligibility criteria 
allowed for a greater streamlining of the process and required greater details from 
Genome Canada with regards to said eligibility guidelines.  Vague wording in the 
Competition I guidelines such as “large-scale” became more detailed in the Competition 
II guidelines.68  While these clarifications seem to explain the higher number of full 
proposals that made it to international peer review between Competitions I and II, with 
31 from Competition I and 64 from Competition II.  It needs to be recalled that 
Competition II was designed to be a pure project Competition.  Where the effectiveness 
of the Competition II model becomes apparent is the efficiency in selecting twice as 
many proposals as Competition I.  By the end of the international review process 34 
64 Warren and Phillips, pg. 6
65 Ibid., pg. 11
66 Ibid.
67 Ibid.
68 Ibid., pg. 7
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successful projects were selected, twice that of Competition I even having taken only two 
weeks longer than Competition I.
The Interim Report also comments on Competition II, noting Genome Canada 
continued to play a significant role in empowering regional centers primarily through 
what the interim report titled “Effective Communications and Outreach Programs”.69 
Genome Canada worked extensively during the Competition II period to help promote a 
brand image that supported both the regional centers and the Genome Canada network as 
a whole.  This served the regional centers in two ways.  First, since Genome Canada was 
centrally spearheading this branding exercise the regional centers did not have to invest 
resources developing regional communications and outreach programs.70  Secondly, this 
also served the regional centers’ goals as it allowed them to broaden their funding 
opportunities by allowing them access to new funding sources by utilizing Genome 
Canada’s outreach programs.
The Interim Report’s findings also suggest a growing federated organizational 
system developing between Genome Canada and its regional centers.  Much like the 
Canadian federal-provincial system, authority was highly decentralized to the regional 
centers for the administration and oversight of genomic research directly, while Genome 
Canada operating as a central authority set agendas, managed funding competitions, 
dispersed funds and dealt with communications and outreach.71 
In summary, the differences between Competitions I and II were minor. 
Nevertheless, significant changes made to the review process after Competition I made it 
possible to review twice as many projects in roughly the same amount of time in 
69 Interim Report, pg. 33
70 Ibid.
71 Ibid.
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Competition II.  Continued outreach and connectivity between the regional centers, 
Genome Canada, and various levels of government in Canada produced greater support 
and cohesion amongst the various agents within this growing genomics research network. 
Consequently, Competition III, which would occur two years later, would result in further 
improvements in efficiency and effectiveness in the Genome Canada Competition 
models.
4.4.3 Competition III
The focus of Competition III, like that of Competition II, was on project funding. 
Efforts at improving the process and documentation for the funding review process 
continued.  Toward that end the registration package was expanded from seven pages to 
ten, doubling in size since Competition I’s Letters of Intent. Warren and Phillips outline 
the timeline for Competition III as follows:
• July 30, 2004 – Request for registration
• November 1, 2004 – Registration packages from Genome Centers due
• November 15, 2004 – Invitation for full applications for projects passing initial review
• January 28, 3005 – Full application due to Genome Canada
• February to March, 2005 – Due diligence review
• March 2005 – Board of Directors decision to send proposals to peer review based on due 
diligence review process
• Early June 2005 – International peer review panel meeting
• Late June 2005 – Board decision on competition winners
• August 25, 2005 – Notification of decision of competition winners
Total time: 13 months72
A number of differences are readily apparent between Competition III and the 
previous competitions.  First, is the extended due diligence review process.  Over the 
course of the three competitions due diligence had become increasingly intensive, and 
while never explicitly explained, it seems logical to presume issues with past projects 
warranted this additional measure. As Warren and Phillips point out for Competition III 
72 Warren and Phillips, pg. 12.
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“Proposals that were deemed unfit according to financial and management criteria were 
either not submitted for peer review or given a chance to be revised and resubmitted.”73 
Registration packages and proposals submitted for Competition III also required clear 
links to eventual commercialization benefits with an expected timeline for the completion 
of the project, with preference given to projects with a lifespan of between three to four 
years.74
The lack of readily available funding by Genome Canada for Competition III 
could be considered indicative of these extended due diligence requirements.  At $167.5 
million dollars Competition III was the most financially intensive funding Competition 
undertaken by Genome Canada, but unlike Competitions I and II where Genome Canada 
had the total amounts of funding in place at the start of the competitions, with 
Competition III Genome Canada did not but remained confident the federal government 
would supply them with the funding necessary.75  Despite its optimism, Genome Canada 
had cautioned the centers that Competition III might be delayed or even cancelled if the 
federal government did not grant sufficient funds.76  Fortunately, the federal government 
awarded Genome Canada $165 million of the $167.5 million required for Competition III 
halfway through the Competition, allowing it to continue without delay.77  An additional 
$100 million follow-up contribution would be made by the federal government to assist 
with upkeep costs of past and present projects; however, those funds were to be reserved 
by Industry Canada and granted annually only as needed.78
73 Ibid., pg. 12.
74 Ibid., pg. 3
75 Ibid., pg. 2
76 Ibid.
77 Ibid.
78 Ibid., pg. 2.
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In the unpredictable world of scientific and technological research not everything 
can be anticipated.  In genomics this is no different, which was why Science Advisory 
Boards (SABs) became another change that took place during Competition III that 
Warren and Phillips outline, and while SABs were seen in Competition II to a lesser 
extent, Competition III was where they became mandatory during project submission. 
SABs were responsible for giving informed and critical advice and guidance to research 
teams once a project encountered an unexpected situation.79  Supported by the regional 
centres, these SABs were to be sufficiently independent of the research teams in order to 
avoid any conflicts of interest.80
Issues such as GE3LS, intellectual property and information sharing also 
expanded in Competition III.  While these issues had always been of interest in the 
general Genome Canada guidelines they became an entrenched part of the registration 
process beginning in Competition III.  These issues rose to prominence amongst the 
regional centers and Genome Canada for a number of reasons.  With regards to GE3LS, 
Warren and Phillips indicate a continual appreciation within Genome Canada for the role 
GE3LS work plays in genomic research and the importance of its considerations.81 
Intellectual property issues were an obvious concern with regards to commercialization 
and who was credible and responsible for a project’s developments.  As for information 
transfer, Genome Canada encouraged the publication of a project’s findings as 
expeditiously as possible to allow for as much usage of the knowledge as possible.  Thus, 
starting in Competition III considerations were added to proposals to consider how 
quickly they could distribute the results of projects.  This also carried an international 
79 Ibid., pg. 12
80 Ibid.
81 Ibid., pg. 4
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element as a notable increase in participation with international projects also encouraged 
or required the release of results to more public venues.
On that point, international collaboration was also a focal point of Competition 
III.  While increased international collaboration had always been an objective of Genome 
Canada it took on a more pressing importance in Competition III.  This shows a general 
maturation of Genome Canada’s system as attention shifted from intra-network 
development and collaboration to international collaboration on major research projects.82
4.4.4 Theme I/ABC Competition
The ABC Competition, following the Theme I call for strategic research themes, 
was created by Industry Canada for Genome Canada to identify strategic research themes 
for targeted research objectives.83  The timeline for the Theme I/ABC Competition as 
outlined by Warren and Phillips was as follows:
• April 1, 2008 – Announcement of competition, request for application
• May 2, 2008 – Deadline for letters of intent to Genome Centers
• May 20, 2008 – Deadline for letters of intent to Genome Canada
• Late May 2008 – Review of letters of intent and decision to invite full applications
• June 2008 – Information sessions
• August 29, 2008 – Deadline for full applications to Genome Centers
• October 3, 2008 – Deadline for full applications to Genome Canada
• November 23, 2008 – Deadline for receipt of outstanding co-funding documentation
• Early December 2008 – International peer review of project proposals
• January 2009 – Decision by Board of Directors of successful projects
• April 20, 2009 – Notice of Award
• July 2009 – Deadline for applicants to be in a position for funding
Total time: 12 months
The ABC Competition model removed the registration process used in Competitions 
II and III and returned to a more sophisticated version of the Letters of Intent model used 
in Competition I.84  During the Theme I call 58 “Expressions of Interest” were received 
82 Ibid.
83 Ibid., pg. 13
84 Ibid.
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by Genome Canada and the Science and Industry Advisory Committee (SIAC), which 
were sorted into eleven themes.85  A Leader was then selected for each of these themes 
and given six months to campaign for their theme and bring together interested 
researchers for said theme.86  These groups of researchers then submitted eleven position 
papers outlining research foci to Genome Canada.87  From this process two themes were 
selected by committee recommendations and the Board of Directors, those being bio-
products and crops, as the focus of the first ABC Competition.88  Shortly thereafter, the 
process of project approval, similar to those of Competitions I, II and III began.89  This 
system succeeded in that the thematic competitive process included explicit needs for 
cooperation, networking and generation of policy interests from outside the research 
network.  
The length of proposals was expanded again to eleven pages, at least two of which 
were required to address GE3LS issues, and in this Competition GE3LS issues had to be 
considered as an integral component that complemented the project’s objectives rather 
than as the limiting factors for the research, which had become the norm in previous 
Competitions.90
The ABC Competition also witnessed Genome Canada more actively pursue 
developing collaborations across the network, actively seeking out synergies and overlap 
and confidentially contacting project leaders to ask whether a partnership appeared 
85 Ibid.
86 Ibid.
87 Ibid.
88 Ibid.
89 Ibid.
90 Ibid.
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logical.91  Warren and Phillips also note a change in the due diligence process that took 
place within the ABC Competition from issues that had arisen from Competition III:
Although not mentioned in the project application guidelines, the due diligence 
evaluation was no longer conducted before the international peer review, but instead at 
the same time.  This change was initiated because of concerns arising in Competition III. 
Discontent was expressed because it was thought that a number of projects with scientific 
merit were dropped from the competition because of the results of the due diligence 
evaluation, which assessed their managerial and financial stability.92
The funding structure for the ABC Competition changed as well.  Industry Canada 
was given control over the $140 million federal grant intended for the ABC Competition 
and required Genome Canada to submit a strategic research portfolio in order to gain 
access to this grant.93  This was the primary reason for the thematic shift in the ABC 
Competition’s model, as this created an intensive procedure for determining Genome 
Canada’s preferred research objectives, which led to the longest timeframe of the 
Competitions.  Despite this, Genome Canada’s KPMG 2009 performance audit report 
suggested Genome Canada continue to hold open competitions to encourage new actors, 
ideas and the recognition of emerging themes, as well as to shorten the approval 
process.94  
91 Ibid., pg. 14
92 Ibid.
93 Ibid.
94 Ibid., pg. 15
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4.4.5 Post ABC Competition/Theme II
Considering the last public competition, the ABC Competition, occurred so 
recently it is too soon to tell what affect this new thematic phase, colloquially referred to 
at present as Post-ABC/Theme II, will have on Genome Canada.  However, it is likely 
that Genome Canada will continue proactively increasing efficiency in the proposal 
selection processes, performing more thematic competitions, and further encouraging 
regional and international cooperation and collaboration.  Also, with the regional centers 
seemingly content with Genome Canada’s present agenda it seems unlikely, barring any 
impossible to predict “Black Swans”95, that there will be any transformative 
breakthroughs in research.  
Early in 2009 Genome Canada was featured in news media as rumors spread that 
the Conservative minority government of the day was considering, given the onset of a 
fiscal crisis and economic recession, cutting the organization’s funding in the new 2009 
budget.96  This turned out to be a mixed truth, for while the federal budget awarded no 
new funding for Genome Canada it continued to supply previously established funding 
agreements made between Genome Canada and previous federal governments. The 
impact this had on Genome Canada’s operations seems minimal.  The current level of 
federal funding is sufficient for Genome Canada to continue funding genomic research, 
especially given that there are also alternative sources of funding that supplement the 
federal government’s funding. In this Post-ABC/Theme II period, the success of Genome 
95 Black Swans are a term given to events that are so statistically improbable that there is no adequate 
means of preparing for their occurrence.  The term was taken from Nassim Nicholas Taleb’s book The 
Black Swan: The Impact of the Highly Improbable (Random House; New York, New York: 2007).
96The Globe and Mail, “Budget erases funding for key science agency”, January 29, 2009: 
http://v1.theglobeandmail.com/servlet/story/RTGAM.20090129.wbudgetscience29/BNStory/budget2009/h
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Canada and its regional centers to access funding from other sources has minimized the 
risks of serious financial constraints resulting from reductions by the federal government.
Table 4.3: Summary of Funding from Competitions
Sources of Funds GBC Genome 
Alberta
Genome 
Prairie
OGI Genome 
Quebec
Genome 
Atlantic
Competition I 42,707,206 n/a 22,783,650 36,874,000 51,755,770 8,748,751
% Genome Canada 21,261,283 
(50%)
n/a 11,391,825 
(50%)
18,282,738 
(50%)
25,787,413 
(50%)
4,221,108 
(48%)
% Province and 
Other
21,445,923 
(50%)
n/a 11,391,825 
(50%)
18,591,262 
(50%)
25,968,357 
(50%)
4,527,643 
(52%)
Competition II 33,802,522 n/a 54,256,924 111,681,965 96,186,116 8,533,528
% Genome Canada 16,738,843 
(50%)
n/a 25,681,356 
(47%)
56,762,424 
(51%)
44,260,642 
(46%)
2,724,250 
(32%)
% Province and 
Other
17,063,679 
(50%)
n/a 28,575,568 
(53%)
54,919,541 
(49%)
51,925,474 
(54%)
5,809,278 
(68%)
Competition III 98,935,112 25,745,919 28,503,651 165,211,071 77,037,183 27,479,418
% Genome Canada 49,349,670 
(50%)
10,658,707 
(41%)
12,426,961 
(44%)
75,572,589 
(46%)
37,551,259 
(49%)
13,086,663 
(48%)
% Province and 
Other
49,585,442 
(50%)
15,087,212 
(59%)
16,076,690 
(56%)
89,638,482 
(54%)
39,485,924 
(51%)
14,392,755 
(52%)
ABC Competition 21,714,195 24,861,616 27,773,060 17,377,748 22,081,872 0
% Genome Canada 10,283,174 
(47%)
11,476,794 
(46%)
13,076,268 
(47%)
7,880,937 
(45%)
10,338,033 
(47%)
0
% Province and 
Other
11,431,021 
(53%)
13,384,822 
(54%)
14,696,792 
(53%)
9,496,811 
(55%)
11,743,839 
(53%)
0
97
This table is a summary of the amount of funding each regional centre received 
throughout each of the funding competitions explained in this chapter.  There are some 
interesting points to consider, with a reminder that the table represents funding acquired 
through Genome Canada competitions only.  Genome Canada has created a roughly 
equal, 50/50 funding scheme from its competitions.  Granted, Genome Atlantic’s not 
getting a project through the ABC Competition is likely an area that needs improvement 
but generally speaking the system seems to have worked according to intent.  There is 
also evidence to suggest regional centres are becoming less reliant on majority Genome 
Canada funding with Genome BC, OGI and Genome Quebec seeing a lowering 
97Genome Canada, “Genome Financial Reporting System”: http://genomereports.ca/section.php?
Lang=En&ID=3&Nav=Section. 
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percentage of Genome Canada funds for projects in later competitions than in earlier 
ones.  The creation of Genome Alberta resulted in half the usual research funds finding 
their way to Genome Alberta rather than Genome Prairie beginning in Competition III, 
but still Genome Prairie did exceptionally well relative to other regional centres in the 
ABC Competition, likely in part contributable to the research focus being agriculture and 
bio-products.  Genome Canada shows itself to be an evolving network seemingly 
succeeding in its intended purposes in a method that still has areas of improvement that 
can continue to be perfected.
4.5 Conclusion
To reiterate, the objective in this chapter has been to provide an overview of the 
level and sources of funding both for Genome Canada and each of the regional research 
centers. The chapter reveals that the entire GCRN system is funded from a vast array of 
governmental and non-governmental sources.  The chapter also reveals that both funding 
levels and funding sources have increased substantially over time both for Genome 
Canada and for the regional centers. The funding commitments of the federal and 
provincial governments are influenced primarily by their fiscal capacities and priorities, 
and to some extent also the special research interests of some provincial governments 
based on what they consider important for the respective economies. The chapter also 
reveals that the creation of Genome Canada and the regional research centers has 
provided a functional research framework within which the federal and provincial 
governments, as well as non-governmental funders, can channel funding to foster and 
facilitate research agendas and projects of importance to each of them.
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Furthermore, the success of Genome Canada and the regional centre’s roles as 
coaches and collaborators for research projects is commendable, and continued progress 
along this path needs to be encouraged for Genome Canada to begin to reach outward 
into international expansions.  Genomic projects of the future are likely to be global or 
issues that affect every person, not limited to national or regional boundaries.  Genome 
Canada and the regional centres need to continue to collaborate internationally and be 
prepared to be a part of or spearhead future international genomic projects.  Fortunately, 
the trend outlined in this chapter suggests that is current path of Genome Canada.
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Chapter 5: Conclusion
The objective in this concluding chapter is to summarize the key findings, briefly 
analyze or comment on the relevance of the findings, discuss some potential directions 
for changes to the funding, structure and research agendas of the GCRN, and to highlight 
some directions for further research. 
5.1 Summary and Analysis of Findings
In summarizing and analyzing the findings of this thesis it is prudent to return to 
the original seven questions posed in Chapter One: 
1. How and why was Genome Canada created? 
2. How is Genome Canada governed?  
3. How is the regional genomic research network structured?
4. When, how and why were the regional centres created?
5. How are the regional centres governed?
6. What is the research focus of each regional centre?
7. How is the genomic research network funded?
The findings related to each of these questions are dealt with in turn below. In addition to 
answering those particular questions, the chapter also devotes some attention to the 
general research question in this thesis, namely what effect did the Canadian federal 
system have on the creation, operation and funding of the GCRN. 
5.1.1 Summary and Analysis of Findings on Questions 1 and 2
The first two questions regarding how and why Genome Canada was created and 
how it is governed were addressed in Chapter Two. In explaining the emergence of 
Genome Canada, the chapter traced the evolution of Canada’s genomic sector from the 
time it was a limited research initiative during the late-80s that began to rise in 
importance due in part to the Human Genome Project. Consequently, gradually Genome 
Canada was established as a national public research agency to foster, facilitate and 
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support genomic research in Canada in partnership with a network of regional research 
centres.  The chapter also revealed that Genome Canada was created in response to 
national and international developments and dynamics in genomics research. As the 
1990s came to a close, private interests began to intersect with the public interests in 
genomics research.  Governments around the world, including Canada, took notice and 
altered their funding practices to create a polycentric and competitive policy space that 
insured no single hierarchical or market oriented command and control system over 
genomic research.  
The concept of the Triple Helix, as described in Chapter Two, was useful in 
explaining why this strategic approach to genomics research occurred in Canada.  A shift 
occurred in the Triple Helix between the pre-Genome Canada period and the period 
following Genome Canada’s genesis.  In the pre-Genome Canada period the Triple Helix 
was adversely affected by a fiscal crisis that reduced the ability of the federal government 
to perform fully its funding role within the Triple Helix. This required the academic helix 
to seek greater support from the industry helix, which led to the problems surrounding 
Celera Genomics.  Following the events surrounding the Celera Genomics period and the 
end of the fiscal crisis, the government helix recognized its failures and realigned itself 
with the needs of the academic helix by creating Genome Canada as a public research 
agency funded by the government.  The end result was that the governmental helix as it 
stands now is operating more in line with the wishes of the genomic agencies of the early 
90’s than the way it operated during the fiscal crisis of the mid- to late-90’s.
In retrospect, one is led to ask whether Genome Canada would have turned out 
the same had there been no fiscal crisis.  The crisis led regional centers to adopt a more 
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formal networked approach to their governance and operations and to seek out alternative 
forms of funding from provincial or industry sources.  Without that fiscal crisis and the 
continuation of full federal funding there may have been no need to move towards a more 
institutionally formal and funding flexible network; rather, they may have remained a 
more informal network that was more heavily dependent on the federal government.  The 
shortage of resources led to a decentralization of functions and the adaptation of the 
network. The emergence of this network was valued by various actors because it was 
believed that it would be more efficient and effective if there were multiple actors 
engaged in collaborative and competitive behavior. In network theory hierarchies have a 
tendency to form bottlenecks as vertical decisions and reactions reach nodes that perform 
less efficiently, or they are incapable of rapidly adapting when a node fails.  As network 
theory posits, networks accept and facilitate the development and operation of multiple 
nodes to extend policy spaces as far and wide as possible.  The assumptions underpinning 
the Networked Federalism model outlined in Chapter One would suggest the importance 
of continuing the process of extending the genomic research network as widely as 
possible, incorporating as many nodes as possible and creating denser regional or 
provincial networks much as Genome B.C. and Genome Quebec have been doing by 
instituting their own smaller regional funding competitions.  In so doing the ability for 
the network to readily adapt, despite the inherent issues with hierarchical government 
bureaucracies, can continue to improve.  For Genome Canada’s positive reputation 
among international genomic research groups to continue to improve it is imperative that 
this experiment in regionalized networked research and networked federalism is 
succeeding.
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5.1.2 Summary and Analysis of Findings on Questions 3, 4, 5 and 6  
Chapter Three examined questions three, four, five and six regarding how the 
Canadian genome network is structured; when, how and why the regional centres were 
created; how the regional centres are governed; and, the research focus of each regional 
centre.  
In the case of question three, that chapter revealed that the genome network has 
been essentially structured as a federated system consisting of a national agency and 
several regional agencies, each of which performed key functions either on their own or 
in relations to each other. This organizational framework was achieved through 
collaboration and coordination within the Triplex Helix. It occurred largely by 
establishing the national agency and consolidating and institutionalizing the existing and 
emergent regional genomic research nodes.  
In the case of question four, regarding when, how and why the regional centres 
were created, both Chapters Three and Four revealed that they were the byproducts of 
Genome Canada’s Competition I at the turn of the millennium.  Genome Canada’s ability 
to access substantial resources from various funding sources made it possible for it to 
provide strategic direction in creating and structuring the regional centres. 
In the case of question five regarding how the network was governed, Chapter 
three revealed that despite some minor differences,  considerable similarity and symmetry 
has existed in the governance frameworks of Genome Canada and each of the regional 
centres.  A few notable differences are evident in the precise configuration and 
composition of their respective governance and operational committees.  The chapter also 
revealed that the research agenda of each regional centre focused on several general topic 
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areas, rather than a single specialized topic area. Nevertheless, each of the regional 
centres tend to have one or two areas of particular interest or specialization based on the 
economic, commercial and industrial bases of their respective regions or provinces. 
The findings regarding question six on the research focus of each regional centre can 
be summarized as follows.  Chapter Three revealed that the key stakeholders within the 
GCRN decided to establish a regionalized network within which each centre was free to 
conduct research on any topic or theme of interest, rather than a regionalized network 
approach within which each regional center would serve as a “center of excellence” for 
each research topic or theme.  This decision was based on the following four key 
considerations:
1. Increasing collaborative elements.
2. Decreasing the risk of groupthink.
3. Increasing the number of nodes which keep bottlenecks from forming.
4. Enhancing the adaptive and flexible governance structure necessitated by a 
“moving target” cycle of adjustments in research themes and funding.  
The first two points relate to concerns that establishing regional ‘centers of excellence’ 
each of which focused only on one major component of the research agenda would result 
in some problems. One such problem was the pooling of researchers with the same 
research interest into one center, thereby limiting access they would have to fellow 
researchers in their field but with different research interests.  A regional network of 
centres that were not limited to a single research topic or theme would likely reduce the 
likelihood that this would happen by increasing contact among researchers across the 
GCRN.  The third consideration relates to concerns regarding over reliance on rigid 
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hierarchical approaches to governance, management and in designing research agendas. 
The network approach promotes redundancy and works to bypass risks associated with 
bureaucratic bottlenecks or node failures.  Finally, the organizational structure was useful 
in dealing with the “moving target” manner of establishing research agendas, research 
funding, and research governance discussed in previous chapters.  
5.1.3 Summary and Analysis of Findings Related to Question 7
In the case of question seven regarding how the research network has been 
resourced, a quick summary of the competitions described in Chapter Four provides some 
important insights. Chapter Four revealed that funding resources for the GCRN has been 
derived from the governmental and non-governmental sectors domestically and 
internationally.  Genome Canada has been very instrumental in distributing funds to the 
projects through the regional centres through a series of research funding competitions. 
Competition I involved the establishment of the five regional genome centers along with 
the creation of the first application process for funding of genomic research projects. 
This first Competition was very open, creating a glut of projects the institution had not 
anticipated, with less than a tenth of those making it through the process.  Competition I 
provided professional management for the regional centers and allowed for the purchase 
of necessary research infrastructure and equipment. However, Competition I’s model was 
inefficient considering the great number of rejected projects.  Such an open model 
demonstrated it was necessary to establish more restrictive criteria for submissions in the 
future.  In all, the “moving target” approach utilized in Competition I would form the 
foundation for future Genome Canada competitions.  
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Competition II is considered the first “true research” Competition. The number of 
projects selected for funding was twice that of Competition I.  Competition II also added 
tighter restrictions to applicants utilizing a registration package method to preempt 
projects that fell outside Genome Canada’s areas of interest.  More importantly, the 
regional centers also became involved in insuring projects submitted would pass Genome 
Canada’s eligibility criteria reinforcing the importance of the regional centers. 
Competition II approved twice as many projects for funding as Competition I in roughly 
the same amount of time, indicating the changes made increased the efficiency of the 
application process.
Competition III was the first Genome Canada competition where funding was not 
set up beforehand, requiring Genome Canada to caution that the Competition might have 
to be delayed if funding did not arrive.  Due diligence thus became a far more important 
and intensive process in Competition III, and the need for clear commercialization 
potential in research projects contributed to a more streamlined and efficient application 
process.  Greater focus on GE3LS issues and international collaboration were hallmarks 
of Competition III.  Compared to Competitions I and II, Competition III used the most 
sophisticated system, showing a general maturation within the network and introducing 
the need to see back-end commercialization from successful projects.
The Theme I/ABC Competition constituted a notable shift in Genome Canada’s 
philosophy and direction regarding the organization, operation and funding of the GCRN. 
Devised by Industry Canada to identify strategic research themes, Theme I, followed by 
the ABC Competition, returned to Competition I’s Letters of Intent model to determine 
themes to focus Canada’s next round of genomic projects; two were eventually selected: 
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bio products and crops.  The ABC Competition also had no funding available upfront. 
Consequently, Genome Canada had to submit a strategic review in order to be granted 
funding from Industry Canada.  This showed a renewed interest in the Genome Canada 
system by Industry Canada, and brings up both a potential merit and flaw.  The merit is 
that this was likely Industry Canada’s way of indicating a preference to work with 
Genome Canada more intensively, thereby further empowering the government helix to 
continue supporting the network.  In recent years, however, concerns have emerged that 
Industry Canada may be placing greater restrictions and recommendations on Genome 
Canada as a first step in reasserting some measure of authority over the institution. 
Whether this will result in positive or negative outcomes remains to be seen.
5.2 Importance of Continuing Federal Government Support for Genome Canada
One of the interesting questions regarding the future of Genome Canada is what 
would be the implications of the federal government discontinuing its support for 
Genome Canada.  Indications are that it would be highly unlikely that the network could 
be financially sustained and maintained in its current form. The first loss under such a 
scenario would undoubtedly be Genome Atlantic.  Having failed to secure any successes 
in recent research funding competitions and existing on backlog projects from Genome 
Prairie, Genome Atlantic would likely be the first loss to the genomic centers.  How 
Genome Prairie and the Ontario Genomic Institute would fare depends largely on the 
response their provinces would have to a post-Genome Canada situation.  Given there is 
no evidence to suggest provincial governments are willing to support these centers to the 
same extent other provincial governments do in other regions (see Genome BC and 
Alberta below) these regional centers would most likely revert to the more informal 
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entities they were during the pre-Genome Canada phase and continue as best they could 
on provincial and other funding.  What is meant by reversion to an informal state is to 
remember the state of the network during the 1990s prior to the creation of Genome 
Canada.  The creation of Genome Canada differentiates the informal from the formal 
period in that Genome Canada created a formal structure within which funding could be 
competed for in a much more established fashion then during the pre-Genome Canada 
period.  As suggested the regional centers likely to survive such a post-Genome Canada 
period would Genome Quebec, Genome BC and Genome Alberta.  Genome Quebec 
receives matched contributions dollar for dollar from the provincial and federal 
governments and has begun, like Genome BC, hosting smaller, more regional 
competitions of regional interest.  Genome BC existed before Genome Canada and has 
maintained its practice of receiving more funding from its provincial government, thereby 
reducing its dependence on Genome Canada.  It is likely Genome BC would become a 
relatively more powerful and influential player in a smaller Canadian genomic context 
with regional competitions hosted by Genome BC continuing where national 
competitions become fewer and fewer.  Genome BC already has a history of hosting 
smaller, regional competitions with its own funding competitions.98
Genome Alberta could also continue to exist independently provided it could 
convince the Alberta provincial government to fund it to the same extent as the British 
Columbia provincial government funds Genome B.C.  There is an important distinction 
to be made here.  Genome Alberta did become independent from Genome Prairie because 
the Alberta provincial government wanted to make sure its provincial funding was going 
98 For examples of Genome BC`s regional competitions see http://www.genomebc.ca/portfolio/timeline/ 
and http://www.genomebc.ca/opportunities/current-funding-competitions/ 
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to research in Alberta’s interests.  However, Genome Alberta is still reliant on Genome 
Canada funding to maintain its current efforts.  Without Genome Canada funding the 
ability for Genome Alberta to survive independently in its current form would depend 
directly on whether the Alberta provincial government would be willing to adopt a more 
B.C. like approach and become the dominant funding source for the regional center. 
While the Alberta provincial government passed on such an opportunity previously, if 
Genome Canada were to lose federal funding it may become a more viable or necessary 
option for the provincial government especially if Alberta wishes to continue pursuing 
significant genomic research.
While this would by and large be a step backwards it could be argued this is 
simply an expression of another fiscal crisis. These centres would likely work to either 
keep Genome Canada afloat or return to lobbying the federal government directly, seeing 
such a setback as a temporary one that could be easily reversed once the economic 
conditions turn more favorable.  What would be interesting to consider is a positive 
outcome in a post-Genome Canada environment in which the national agency (i.e., 
Genome Canada) would no longer exist.  For this to occur, the remainder of the network 
consisting of just the regional centers will have to become sufficiently advanced that the 
need for a centralized authority becomes obsolete.  An idealistic idea to be sure, as this 
would require the regional centers to  overcome their dependence on Genome Canada for 
primary funding and the development of a research proposal funding process that insures 
a balanced selection of appropriate research projects.  If they could deal with those two 
important issues, it is possible that a highly decentralized, self-sustaining network of 
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regional centers capable of surviving without direct federal and provincial funding could 
continue to exist.
One final scenario to consider is a Genome Canada independent of any 
government funding.  This is unlikely to occur simply due to the extensive costs of the 
research being conducted and Genome Canada being a public corporation; the distinction 
between a public corporation and a Crown corporation is that Genome Canada is not tied 
to the governmental bureaucracy in any direct fashion other than funding. However, if 
some of their research projects developed sufficient commercial viability and Genome 
Canada effectively invested available capital with the intention of developing a self-
sustaining fund, then Genome Canada could conduct competitions without any funding 
from government sources.  There are two things to consider here.  First, it would not 
grant Genome Canada absolute autonomy because the federal government would still 
maintain control over regulations regarding genomic research.  Second, with regards to 
networked federalism theory this does not seem to be an ideal situation to aspire for, as it 
could hold the potential of eliminating a number of key nodes associated with 
government bureaucratic systems and networked federalism maintaining as many 
connections and nodes as possible is the ideal situation.  Independence from 
governmental funding for future research competitions would be the only foreseeable 
benefit.
Hopefully the economic downturn of the past few years can be mitigated before it 
becomes a fiscal crisis.  The 1990’s clearly showed how lack of funding from the federal 
government carries the very real danger of hampering research initiatives and potentially 
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losing valuable scientific experts and laboratories to countries with governments that 
devote more financial resources to research such as the United States, Britain or China.
5.3 The Effects of Canadian Federalism on the Structure and Resourcing 
As mentioned earlier two options existed for the structure of the network, one 
with regional centres and the other with centres of excellence, with the former being used 
over the latter.  One of the reasons for this choice can be linked to Canada’s federal 
structure.  Regional bodies allowed provincial governments a clear indicator of where 
their research dollars were going and allowed the development of focused research 
interests that coincided with provincial research interests.  A central body permitted a 
clear agent to deal with the federal government and oversee project funding, as well as 
allowing the central agent to deal with matters that would have taken time from research 
projects at the regional level.  These factors led to the GCRN to use Canada’s federal 
model as a framework upon which to create a network that would have obvious 
connections between regional centers-central agent, regional centers-provincial 
governments, central agent-federal government, etc.
The network also emphasized the need for government to work with research 
interests in a mutually beneficial manner.  The creation of a network separate yet linked 
to Canada’s federal system allowed the response time the GCRN was looking for while 
still granting federal and provincial governments influence over research interests that 
coincided with governments’ interests.  It also made Genome Canada the central authority 
in international collaborations with the GCRN, permitting the GCRN to become more 
involved in international projects.  A system that harmonized the research network with 
government authorities further reduced possibilities for conflict and encouraged a more 
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inclusive environment.  Basing Genome Canada around Canada’s federal system allowed 
a stable network with clear associations and interests to form permitting Genome Canada 
to be best equipped to engage in research interests both domestic and global.
5.4 Potential Areas for Further Research
Given the novel nature of this research, there is a need for further research in at 
least four areas.  The first comes out of what was introduced in the opening chapter that 
the focus of this thesis is on organizational evolution, not on the actions of individual 
actors that influenced said evolution.  There is no question that policy entrepreneurs, 
acting individually and collectively, were responsible for achieving agreed upon 
objectives. Performing further research into whom these actors may have been and what 
roles they fulfilled during the creation and evolution of the processes during the pre-
Genome Canada and Genome Canada periods would be valuable.
Second, further research could be done on whether the federal government chose 
the right model for research funding. This research would focus on the issue that arose 
just prior to Genome Canada’s creation on whether the system should be based on a 
model whereby each centre specialized in one pre-determined areas, or a model whereby 
the precise research focus of each regional centre would be based on the focus of their 
research that succeeded in accessing funds through the funding competitions. 
As suggested at the conclusion of Chapter Four a third interesting aspect of 
genomic research that merits further research is the precise focus of the research agenda 
of the GCRN. Some of that research agenda is reaching a point to where it is being 
considered an integral part in global spanning research projects, including, for example, 
human longevity research, stem cell and nanotechnology research, which has produced 
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an increasing array of articles and books indicating a growing interest in such research.99 
The example of life extension has fascinated humanity for centuries, and for the first time 
in recorded history there may actually be substantial scientific evidence to suggest such 
procedures could be commercially viable within the next generation.100  Even the 
possibility of such research being scientifically feasible, let alone commercially viable, 
demands an examination of the various effects this sort of research might have on 
established laws, politics, morals, economics, practically every aspect of our society.  If it 
were possible to grant the average human even an additional ten years of productive life, 
that little difference could mean substantial changes to the way society behaves, and yet it 
is likely such serious investigations could be bypassed until they are long overdue simply 
due to the traditional stance that high technology is farfetched.  There are serious 
implications to such possibilities, and without proper consideration there could be 
extremely problematical effects on a society ill prepared for a future where such 
technologies are available and potentially commonplace.
Finally, to expand on the previous point but at a practical level the most obvious 
avenue for future research is that there are other high technology sectors that are 
beginning to become more important and might likewise benefit from governance and 
operational frameworks similar to Genome Canada.  Analyses could be done on the 
feasibility of utilizing the Genome Canada model for these other sectors in an effort to 
mirror the successes Genome Canada amassed while potentially averting or mitigating 
the trial and error methods embodied in the moving target model used during Genome 
Canada’s institutional evolution that were necessary for such a first time project.  In just 
99 Aubrey De Grey, Ending Aging: the Rejuvenation Breakthroughs That Could Reverse Human Aging in 
Our Lifetime (St. Martin’s Press: 2007)
100 “How to Live Forever”, Science & Technology: abolishing aging, The Economist (January 3rd, 2008)
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over a decade Canada went from being inconsequential in the international genomic 
research agenda to being a leading player in a number of important sectors, clearly 
indicating that the process from pre-Genome Canada through Genome Canada’s four 
thematic evolutions greatly increased the ability for technology sectors to advance. 
Could this system be applied to other technological sectors?  If so, the results would be 
beneficial and worthy of consideration.
All such research would provide additional insights into Genome Canada, a 
fascinating institution that developed through a concerted effort at collaboration and 
coordination of multiple stakeholders for a common goal.  The choices made during this 
institution’s evolution were also well thought out with plenty of opportunity for feedback 
and flexibility, and the institution seems to fit as an ideal case study for the success of a 
networked federalized research system. Sometimes, politics is not the story of why 
40,000 people took to the streets, but rather why they did not; this is the case with 
Genome Canada, with the right decisions being made and an excellent example being set. 
The system is not perfect, but seems adequately robust and flexible to adapt to some of 
the challenges that may emerge in the near future.
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